HR-Positive Advanced Breast Cancer
- The goals of care for patients with hormone receptor (HR)-positive advanced breast cancer include prolongation of disease-free and overall survival, amelioration of symptoms, and improvement in quality of life.
- Use of endocrine therapy as an initial strategy, when clinically appropriate, is preferable, owing to both the expected clinical activity and favorable safety profile.
- Therapeutic strategies combining endocrine therapies with novel agents targeting aberrant molecular pathways, to overcome both de novo and acquired resistance to endocrine therapies, are promising and aim to improve outcomes for patients.
- Chemotherapy is appropriate for patients with HR-positive advanced breast cancer and an adequate performance status when there is evidence of endocrine resistance or intolerance to available endocrinebased treatment approaches, symptomatic disease, or visceral crisis.